Clinical Trials Search Tool

A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to < 18 years of age

Disease/Condition: SARS-COV-2

Location: Gresham

Ages: 12-18 years of age

Enrollment Opens: 05-30-2022

Enrollment Closes: TBD

Description:

A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to < 18 years of age

Study ID: mRNA-1273-P203

To Enroll: Contact Cyn3rgy Research at; 503-907-2179 ext. 2 or visit us on the web at http://www.cyn3rgy.com

Posted by: Cyn3rgy Research | http://www.cyn3rgy.com